Clinical Trials Logo

Clinical Trial Summary

This study is designed to evaluate the safety and efficacy of deflazacort in participants with LGMD2I. Most participants enrolled will have a screening visit and 3 additional visits (after 1, 13, and 26 weeks of treatment).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03783923
Study type Interventional
Source PTC Therapeutics
Contact
Status Terminated
Phase Phase 3
Start date October 31, 2019
Completion date January 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT01403402 - Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Completed NCT02635321 - MRI and Muscle Involvement in Patients With Mutations in GMPPB N/A
Completed NCT00873782 - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy Phase 1
Completed NCT00457912 - Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy N/A
Not yet recruiting NCT06399770 - The Role of Muscle Ultrasound in Assessment of Sample of Patients With Limb-girdle Muscular Dystrophy
Completed NCT04054375 - Weekly Steroids in Muscular Dystrophy Phase 2
Recruiting NCT00390104 - Molecular Analysis of Patients With Neuromuscular Disease
Recruiting NCT06246513 - A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE) Phase 3
Completed NCT00104078 - Study Evaluating MYO-029 in Adult Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT04475926 - A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
Completed NCT02759302 - MRI on Persons With Mutations in POMT2 Gene (LGMD2N) N/A